Launched from the ExploraMed incubator based in Mountain View, California, X9, Inc. is a privately held medical technology company focused on advancing vascular access and patient care in dialysis and ...
Stuart Mott, LPN, is the author of the article in NN&I's March 2013 issue, "Considerations at initiations of cannulation." He is a vascular access nurse from Millesburg, Mo. -by Rebecca Zumoff ...
Fish oil, aspirin not effective for AVF failure treatment The study suggests that neither fish oil nor aspirin can be recommended for the prevention of AVF failure. For reducing arteriovenous fistula ...
It is now clear that the nephrology community has reached a consensus regarding the arteriovenous fistula (AVF)—it is the preferred dialysis access for hemodialysis patients. Indeed, an increasingly ...
Haemodialysis vascular access is a 'lifeline' for almost 2 million patients worldwide; yet given the substantial problems associated with access dysfunction, vascular access is also the Achilles heel ...
San Juan Capistrano, Calif.--Two devices for creating minimally invasive dialysis access--the Ellipsys® Vascular Access System and the WavelinQ™ 4F System--demonstrated high rates of technical success ...
In a related press release, lead author Gerald A. Beathard, MD, PhD, of the University of Texas Medical Branch, said, “The dramatic difference in durability between the endovascular fistulas and the ...
WALLINGFORD, Conn., Nov. 12, 2025 (GLOBE NEWSWIRE) -- X9, Inc. today announced positive results from its first-in-human clinical feasibility study evaluating the X9 Ultrasound System with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback